Searched for
LUPIN PHARMA
Sunil Singhania-backed Abakkus Flexi Cap Fund increases stake in HDFC Bank, RIL and 29 others in MaySunil Singhania-backed Abakkus Flexi Cap Fund significantly increased its holdings in HDFC Bank and Reliance Industries during May. The fun...- Capitalmind Flexi Cap Fund adds Nestle India and 10 others, exits SBI and 14 others in MayCapitalmind Flexi Cap Fund made significant portfolio adjustments in May. The fund welcomed Nestle India and eleven new stocks. It also div...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- 6 pharma stocks that Bernstein sees up to 40% upside potential. Do you own any?Bernstein initiated coverage on six pharma stocks, expressing a positive outlook on the Indian healthcare sector driven by AI, innovation i...
- Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sectorBernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...
- Bank Nifty near key resistance zone; breakout above 54,300 crucial: Ajit MishraIndian equity markets are consolidating within a narrow range, with Nifty struggling to break 24,000 and Bank Nifty showing relative streng...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Mutual funds cut technology sector exposure to 8-year low in April. Is AI disruption reshaping sentiment?Mutual funds have significantly reduced their technology sector exposure to an eight-year low, driven by concerns over AI disruption, slowi...
- Doing more with less is India Inc's new mantra to beat tough timesPrioritising efficiency, Indian enterprises are reshaping their spending habits. Non-essential travel and expenses are being minimized, whi...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Small & midcaps rally! Wockhardt, Coforge, other stocks surge up to 14%. Do you own any?Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- El Nino impact: Which stocks will burn & which will fire up as market braces for heat waveIndia faces a strong El Niño, threatening below-normal rainfall and impacting agriculture. While rural-linked sectors like two-wheelers and...
- Two Trades for Today: A leading pharma firm for a 5.75% rise, a mid-cap online insurance stock for a gain of almost 6%Our technical analysts identify select stocks on every trading day that may gain momentum even in volatile markets. Here are the technical ...
- Lupin launches generic anti-diabetic tablets in USPharma major Lupin has launched its generic anti-diabetic medicine in the United States. The medicine is dapagliflozin and metformin hydroc...
- Bain Capital sole contender for Vitabiotics buyBain Capital has emerged as the frontrunner to acquire Vitabiotics, as rival bidders TPG Capital and EQT exit the process, potentially lowe...
- Lupin Pharma partners with Endoceutics to commercialise Intrarosa in CanadaIntrarosa is Endoceutic's flagship product indicated for the treatment of postmenopausal vulvovaginal atrophy.
Load More
